Skip to main content

Battling Pancreatic Cancer

Premium

National Foundation for Cancer Research scientist Michael Sporn is working on a new class of anti-cancer drugs for the prevention of pancreatic cancer. Sporn, who is known at NFCR as "the father of chemoprevention," and his team at Dartmouth Medical School, have designed and synthesized triterpenoids — synthetic compounds that target and inhibit biological processes like inflammation, which play a role in the formation of the disease. "Recently, the researchers demonstrated that the triterpenoids, CCDO-Me and CCDO-EA, inhibited important inflammatory molecules in pancreatic cell lines and slowed the development of the harmful effects of pancreatic cancer in laboratory models that closely resemble the disease in humans," the Foundation says. Now the researchers are working on figuring out the mechanism by which triterpenoids work, and whether they can be used with standard pancreatic cancer therapies to make them more effective.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.